ReCOV

ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.[1][2][3][4]

ReCOV
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

References
  1. Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov
  2. Clinical trial number NCT05084989 for "Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)" at ClinicalTrials.gov
  3. Allott A, McDonald L (24 June 2021). "New Covid-19 vaccine developed in China is being tested on Kiwis". Stuff. Retrieved 23 December 2021.
  4. "Coronavirus: China-made 'ReCov' vaccine may be better than Pfizer-BioNTech's, New Zealand doctor says; Sydney faces 'scariest period' of pandemic". South China Morning Post. 24 June 2021. Retrieved 23 December 2021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.